You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Blood and immune system conditions
  5. Blood and bone marrow cancers

Obinutuzumab in combination with chlorambucil for untreated chronic lymphocytic leukaemia

  • Technology appraisal guidance
  • Reference number: TA343
  • Published:  02 June 2015
  • Guidance
  • Tools and resources
  • Information for the public
  • Evidence
  • History

Leukaemia (chronic lymphocytic) - obinutuzumab (with chlorambucil, 1st line) [ID650]: final appraisal determination document

Leukaemia (chronic lymphocytic) - obinutuzumab (with chlorambucil, 1st line) [ID650]: final appraisal determination document Leukaemia (chronic lymphocytic) - obinutuzumab (with chlorambucil, 1st line) [ID650]: final appraisal determination document
11 March 2015
(139.81 Kb 40 sec)

Adobe Acrobat reader required.

  Adobe Acrobat reader required.

This page was last updated: 09 March 2015

Back to top